Treatment of osteoporosis with fluorides;Therapie der osteoporose mit fluoriden

Wiener Medizinische Wochenschrift

Volumn 150, Issue 3, 2000, Pages 42-52

  Schulz III, W ^a  

^a KLINIKUM BAMBERG   (Germany)

Author keywords

Combination of fluorides with anti resorptive agents; Fluorides (NaF MFP); Pharmacokinetics of fluorides; Principle of low dosage side effects; Trabekular bone

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE; FLUORIDE SODIUM; FLUOROPHOSPHATE; PAMIDRONIC ACID; PARATHYROID HORMONE; PROGESTERONE; STANOZOLOL; VITAMIN D;

ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFECT; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; OSTEOPOROSIS;

ANABOLIC AGENTS; BONE REMODELING; CALCIUM; CLINICAL PROTOCOLS; CONTROLLED CLINICAL TRIALS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FLUORIDES; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; PROSPECTIVE STUDIES; STANOZOLOL; VITAMIN D;

EID: 0034030146     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. (1) Abendroth K: Fluor in der Therapie der Osteoporose. In Schulz W, Deuber HJ: Osteoporose, Krankheitsbild und therapeutische Möglichkeiten. München-Deisenhofen, Dustri-Verlag Dr K Feistle, 1993; pp 41-53.
2. (2) Baylink DJ, Finkelman RD, Mohan S: Growth factors to stimulate bone formation. J Bone Miner Res 1993; Suppl. 2:565-572.
3. (3) Baylink DJ: Sodium fluoride does not increase human bone cell proliferation or protein synthesis in vitro. Calcif Tissue Int 1992; 50(1):96-97.
4. (4) Beek von E et al: The effect of alendronate on the osteoclastogenic potential of the bone marrow in mice. Bone 1995; 17:597-618.
5. (5) Black DM et al: Design of the Fracture Intervention Trial. Osteoporos Int 1993; Suppl 3:29-39.
6. (6) Bongers N, Raymakera JA, Rijk von PP, Duwrems SA: Effects of combination therapy with bisphosphonate and sodium monofluorphosphate on bone mass in osteoporosis World Congress on Osteoporosis, 18./23. May, Amsterdam (1996).
7. 3 und Kalzium bei Patienten mit Postmenopausen-, seniler und idiopathischer Osteoporose. Quartum Colloquium Osteologicum Jenense, Tagungsberichte, Friedrich Schiller-Universität Jena, 35.48 (1991).
8. (8) Dambacher MA, Schacht E, Schmidt R, Olah AJ: Kann die Fluoridmedikation durch zusätzliche Gaben von aktiven Vitamin D-Metaboliten verbessert werden? Aktuelle Rheumatologie 19, Stuttgart-New York, Thieme, 1994, (Suppl.); pp 35-36.
9. (9) Deuber HJ: Studienergebnisse zum Einsatz von Calcitriol zur Therapie der Osteoporose. In Schulz W, Deuber HJ (Hrsg): Osteoporose, Krankheitsbild und therapeutische Möglichkeiten. München-Deisenhofen, Dustri-Verlag Dr K Feistle, 1993: pp 77-82.
10. (10) Delling G, Grothe HJ, Amling M, Hahn M, Vogel M: Morphologie der Osteoporose. In Schulz W, Deuber HJ (Hrsg): Osteoporose, Krankheitsbild und therapeutische Möglichkeiten. München-Deisenhofen, Dustri-Verlag Dr K Feistle, 1993; pp 1-14.
11. (11) Dure-Smith BA, Farley SM, Linkhart SG, Baylink DJ: Fluoride treated patients become calcium deficient despite calcium supplements: correction with 1,25 vitamin D3. In: Osteoporosis 1993. Fourth International Symposion on Osteopororis and Consensus Develop. Conference Hong Kong, Christiansen C, Riis B, 1993; pp 146-147.
12. (12) Einhorn TA, Wakley GK, Linkhart S, Rush EB, Maloney S, Faierman E, Baylink DJ: Incorporation of sodium fluoride into cortical bone does not impair the mechanical properties of the appendicular skeleton in rats. Calif Tissue Int 1992; 51:127-131.
13. (13) Ericsson Y: Therapie und Prophylaxe der Osteoporose mit kompatiblen Fluor-und Calciumverbindungen. Med Orthop Techn 1982; 102:9-12.
14. (14) Eriksen EF, Hodgson SF, Riggs BL: Treatment of Osteoporosis with Sodium Fluoride In: Osteoporosis. New York, Raven Press, 1988; pp 415-456.
15. (15) Farley JR, Tarbaux NM, Lau KHW, Baylink DJ: Monofluorosphosphate is hydrolyzed by alkaline phosphatase and mimics the actions of NaF on skeletal tissues in vitro. Calcif Tissue Int 1987; 40: 35-42.
16. (16) Farley SM, Wergedal JE, Farley JR, Javier GN et al: Spinal fractures during fluoride therapy for osteoporosis: Relationship to spinal bone density. Osteoporos Int 1992; 2:213-218.
17. (17) Farley JR, Wergedal, JE, Baylink DJ: A review of evidence for anabolic actions of calcitonin on bone and new evidence for anabolic calcitonin-fluoride interactions Osteoporosis. Fourth Internatational Symposion on Osteoporosis and Consensus Develop. Conference, Hong Kong. Christiansen C, Riis B, 1993: pp 348-350.
18. (18) Frost HM: The ADFR concept and monitoring it. In Jee WSS, Parfitt AM: Bone Histomorphometry, 3. Int. Workshop Sun Valley, Metab Bone Dis Res 1980; 2 (Suppl.):317-321.
19. (19) Fratzl P, Schreiber S, Roschger P, Lafage MH, Rodan G, Klaushofer K: Effects of Sodium Fluoride and Alendronate on the Bone Mineral in Minipigs: A Small-Angle X-Ray Scattering and Backscattered Electron Imaging Study. Journal of Bone and Mineral Research 1996; 11:248-253.
20. (20) Fuchs C, Haase W, Maurer H: Pharmakokinetik eines Fluorid-Calcium-Präparates zur Behandlung der Osteoporose. Arzneimittelforschung 1984; 34:832-835.
21. (21) Fuchs C, Heimann G, Tonn R: Relative Bioverfügbarkeit von Fluorid bei gleichzeitiger Applikation von Calcium. Orthop Prax 1982; 18:738-741.
22. (22) Gertz BJ et al: Clinical pharmacology of alendronate sodium. Osteoporos Int 1993; Suppl 3:13-16.
23. (23) Gonelli S, Cepollaro C, Montomoli M, Gennari L, Montagnani A, Palmieri R, Gennari C: Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study. Clinical Endocrinology 1997; 46:55-61.
24. (24) Gutteridge DH, Kent GN, Prince RL, Nicholson GC, Stewart GO, Jones CE, Bhagat CI, Stuckey BG, Retallack RW: Fluoride treatment of osteoporosis: cyclical non-blinded or continuous blindes studies? Osteoporosis Int 1993; 215-217.
25. (25) Heaney RL: Fluoride and osteoporosis. Ann Intern Med 1994; 120:689-690.
26. (26) Hümpfner A, Rebstöck W, Deuber HJ, Ohrisch G, Schulz W, Delling G: Therapie der primären Osteoporose mit dem Anabolikum Stanozolol: Eine Alternative zu Natriumfluorid? Quartum Collegium Osteologicum Jenense. Tagesberichte, Universitätsverlag Jena, 1991; pp 74-100.
27. (27) Hümpfner A, Hummel S, Schulz W: Einsatz der Anabolika als therapeutische Modalität bei der primären (postmenopausalen/präsenilen) Osteoporose. In Schulz W, Deuber HJ (Hrsg): Osteoporose, Krankheitsbild und therapeutische Möglichkeiten. München-Deisenhofen, Dustri-Verlag Dr K Feistle, 1993; pp 105-136.
28. (28) Johansson AG, Lindh E. Blum WF, Kollerup G, Sorensen OH, Ljunghall S: Effects of Growth Hormone and Insulin-Like Growth Factor I in Men with Idiopathic Osteoporosis. J Clin Endocrinol Metabol 1996; 81:44-48.
29. (29) Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C et al: Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 1992; 305:1124-1128.
30. (30) Kleerekoper M, Peterson EL, Nelson DA, Philips E, Schork MA, Tilley BC, Parfitt AM: A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1991; 1:155-161.
31. (31) Kleerekoper M, Mendlovic B: Sodium fluoride theraOpy of postmenopausal oseoporosis. Endocr Rev 1993; 14:312-323.
32. st Nat Scientific Meeting of the Assoc of Rheumatol Health Profession, Orlando, Florida, USA, Oct. 18-22. Arthrit Rheumatism 1996; 39(Suppl. 9):138.
33. (33) Lems WF, Jacobs WG, Bijlsma JWJ, Croone A, Haanen HCM, Houben HHML, Gerrits MI, van Rijn HJM: Effect of Sodium Fluoride on the Prevention of Corticosteroid-induced Osteoporosis. Osteoporos Int 1997; 7:575-582.
34. (34) Libanati CR, Lay KHW, Baylink DJ: A strategy to develop an optimized therapeutic regimen for fluoride. Osteoporosis, 4th International Symposion on Osteoporosis and Consensus Develop Conference Hong Kong. Christiansen C, Riis B, 1993; pp 424-427.
35. (35) Liberman U et al: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333:1437-1443.
36. (36) Liote F, Bardin C, Liou A, Brouard A, Terrier JL, Kuntz D: Bioavailability of fluoride in postmenopausal women: comparative study between sodium fluoride and disodium monofluorophosphate-calcium carbonate. Calcif Tissue Int 1992; 50:209-213.
37. (37) Mamelle N, Dusan R, Martin JL, Prost A et al: Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988; 11:361-365.
38. (38) Marie PJ, De Vernejoul MC, Lomry A: Stimulation of bone formation in osteoporosis patients treated with fluoride associated with increased DNA synthesis by osteoblastic cells in vitro. J Bone Miner Res 1992; 7:103-113.
39. (39) Meunier PJ, Sebert JL, Reginster JY, Avouac B, Briancon D, Fauquert P. Appelboom T, Netter P, Loeb G, Rouillon A, Barry S and the FAVOS Study Group: Fluoride salts compared to calcium-vitamin D in the treatment of established postmenopausal osteoporosis; the FAVOS Study. Osteoporosis Int 1996; 6(Suppl. 1):251.
40. (40) Meunier PJ, Boivin G: Fluoride salts for vertebral osteoporosis: the benefit-to-risk ratio depends on the cumulative dose reaching bone. Osteoporosis Int 1993; 3:211-214.
41. (41) Meunier PJ: Fluoride salts and osteoporosis. Osteoporosis, 3. International Symposium of Osteoporosis, 1990; 1308-1312.
42. (42) Meunier PJ: Bone-forming agents. Internat. Congress series 1118, Amsterdam, Excerpta Medica, Elsevier, 1996; 305-313.
43. (43) Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, Loeb G, Rouillon A, Barry S, Evreux JC, Avouac B, Marchandise X and the FAVOStudy Group: Fluoride Salts are no Better at Preventing New Vertebral Fractures than Calcium-Vitamin D in Postmenopausal Osteoporosis: The FAVOStudy. Osteoporos Int 1998; 8: 4-12.
44. (44) Pak CYC, Sakhaee K, Piziak V, Peterson RD, et al: Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial. Ann Intern Med 1994; 120: 625-632.
45. (45) Pak CYC, Sakhaee K. Adams-Huet B, Piziak V, Peterson RD, Poindexter BS: Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Int Med 1995; 123:401-408.
46. (46) Reginster JY, Meurman L, Zegels B, Rovati LC, Minne HW, Giacovelli G, Taquet AN, Setnikar I, Colette J, Gosset C: The Effect of Sodium Monofluorophosphate plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis. Annals of Internat Med 1998; 128:1.
47. (47) Resch H, Libanati C, Farley S, Bettica P, Schulz E, Baylink DJ: Evidence that fluoride therapy increases trabecular bone density in a peripheral skeletal site. J Clin Endocrin Metab 1993; 76(6): 1622-1624.
48. (48) Reutter FW, Siebenmann R: Die Wirkung von Natriumfluorid bei metabolischen Knochenerkrankungen. Helvet Med Acta 1965; 32:493-497.
49. (49) Riggs BL, Hodgson SF, Eastell R: The Role of sodium fluoride in the treatment of Ossteoporosis. Clinical disorders of bone and mineral metabolism 1984; 605-612.
50. (50) Riggs BL, Hodgson SF, O'Fallow WM, Chao EYS et al: Effects of fluortde treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322:802-809.
51. (51) Riggs BL, O'Fallow WM, Lane A, Hodgson SF et al: Clinical trial of fluoride thrapy in postmenopausal osteoporotic women: Extended observations and additional analysis. J Bone Min Res 1994; 9: 265-275.
52. (52) Ringe JD: Monofluorophosphate prevents fractures in postmenopausal osteoporosis. In Genazzani AR et al (eds): Current Research in Gynecology and Obstetetrics. Casterton Hall, The Parthenonon Publ Group, 1991; pp 527-531.
53. (53) Ringe JD: Neues Konzept in der Osteoporosetherapie. Arznelmitteltherapie 1996; 14: 174-178.
54. (54) Ringe JD: Alendronsäure - Neue Perspektiven in der Therapie der Osteoporose Arznelmitteltherapie 1996; 14:354-359.
55. (55) Ringe JD, Dorst A. Kipshoven C, Rovati LC, Setnikar I: Avoidance of Vertebral Fractures in Men with Idiopathic Osteoporosis by a Three Year Therapy with Calcium and Low-Dose Intermittent Monofluorophosphate. Osteoporos Int 1998; 8:47-52.
56. (56) Rodan GA et al: Preclinical pharmacology of alendronate. Osteoporos Int 1993; (Suppl. 3):7-12.
57. (57) Sansoni P et al: Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995; 10:1719-1725.
58. (58) Sato M et al: Bisphosphonate action - alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88:2095-2105.
59. (59) Schacht E: Die Differentialtherapie von Osteoporosen - ein Überblick auf der Basis neuerer Erkenntnisse zur Pathogenese. Zeitschr Rheumatologie 1994; 53:274-298.
60. (60) Schulz W, Deuber HJ, Schmidt M, Delling G: Controlled double blind follow-up study of sodium fluoride (NaF) combined with calcitriol (1,25) in postmenopausal osteoporosis (PO) over 24 months. 28. Symposium Deutsche Gesellschaft für Endokrinologie, Heidelberg, 7. bis10. März 1984. Ada endocrinologica 1984; 105(Suppl. 264): 15-16.
61. 3) und Osteoporose. In Schulz W, Deuber HJ: Osteoporose, Krankheitsbild und therapeutische Möglichkeiten. München-Deisenhofen, Dustri-Verlag Dr K Feistle, 1993; pp 54-76.
62. (62) Schulz W: Behandlung der Osteoporose mit Bisphosphonaten (Diphosphonate). In Schulz W, Deuber H. J: Osteoporose, Krankheitsbild und therapeutische Möglichkeiten. München-Deisenhofen, Dustri-Verlag Dr K Feistle, 1993: pp 83-104.
63. (63) Setnikar I, Maurer H: Bioequivalence of sodium monofluorophosphale with sodium fluoride and compatibility with calcium. Arzneimittelforschung 1990; 40:994-999.
64. (64) Setnikar IM, Ringe JD: Fluorverbindungen. Arzneimitteltherapie 1995; 13(3):73-79.
65. (65) Ziegler R: Was ist gesichert in der Behandlung der Osteoporose der Frau in der Menopause? Internist 1993; 34:18-24.
66. (66) Ziegler R: Stellenwert der Fluoridtherapie bei Osteoporose. In Seidel MJ, Kraenzlin ME (Hrsg): Osteoporose - Moderne Diagnostik -therapeutische Konsequenzen für Klinik und Praxis. 1. Interdisziplinäres Osteoporose-Symposium. Basel, Karger 1995; pp 69-74.